Pruritus in primary biliary cholangitis is under-recorded in patient medical records.

CHOLESTASIS CHOLESTATIC LIVER DISEASES EPIDEMIOLOGY HEPATOBILIARY DISEASE QUALITY OF LIFE

Journal

BMJ open gastroenterology
ISSN: 2054-4774
Titre abrégé: BMJ Open Gastroenterol
Pays: England
ID NLM: 101660690

Informations de publication

Date de publication:
27 Mar 2024
Historique:
received: 27 10 2023
accepted: 26 01 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 27 3 2024
Statut: epublish

Résumé

Cholestatic pruritus in primary biliary cholangitis (PBC) reduces patients' health-related quality of life (HRQoL). Despite this, existing research suggests that pruritus is under-recorded in patients' health records. This study assessed the extent to which pruritus was recorded in medical records of patients with PBC as compared with patient-reported pruritus, and whether patients reporting mild itch were less likely to have pruritus recorded. We also evaluated clinico-demographic characteristics and HRQoL of patients with medical record-documented and patient-reported pruritus. This cross-sectional study used clinical information abstracted from medical records, together with patient-reported (PBC-40) data from patients with PBC in the USA enrolled in the PicnicHealth cohort. Medical record-documented pruritus was classified as 'recent' (at, or within 12 months prior to, enrolment) or 'ever' (at, or any point prior to, enrolment). Patient-reported pruritus (4-week recall) was assessed using the first PBC-40 questionnaire completed on/after enrolment; pruritus severity was classified by itch domain score (any severity: ≥1; clinically significant itch: ≥7). Patient clinico-demographic characteristics and PBC-40 domain scores were described in patients with medical record-documented and patient-reported pruritus; overlap between groups was evaluated. Descriptive statistics were reported. Pruritus of any severity was self-reported by 200/225 (88.9%) patients enrolled; however, only 88/225 (39.1%) had recent medical record-documented pruritus. Clinically significant pruritus was self-reported by 120/225 (53.3%) patients; of these, 64/120 (53.3%) had recent medical record-documented pruritus. Patients reporting clinically significant pruritus appeared to have higher mean scores across PBC-40 domains (indicating reduced HRQoL), versus patients with no/mild patient-reported pruritus or medical-record documented pruritus. Compared with patient-reported measures, pruritus in PBC is under-recorded in medical records and is associated with lower HRQoL. Research based only on medical records underestimates the true burden of pruritus, meaning physicians may be unaware of the extent and impact of pruritus, leading to potential undertreatment.

Identifiants

pubmed: 38538090
pii: bmjgast-2023-001287
doi: 10.1136/bmjgast-2023-001287
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: UG, HTS, RvM, JL, JF-B, LM and AM are employees of, and hold shares in, GSK. DP is an employee of GSK. JNH was an employee of GSK at the time of manuscript development and holds shares in GSK. CLR, MT and HSF are or were employees of, and hold stock options in, PicnicHealth.

Auteurs

Usha Gungabissoon (U)

GSK, London, UK usha.2.gungabissoon@gsk.com.

Helen T Smith (HT)

GSK, London, UK.

Robyn von Maltzahn (R)

GSK, London, UK.

John Logie (J)

GSK, London, UK.

Liyuan Ma (L)

GSK, Collegeville, Pennsylvania, USA.

Dhirishiya P (D)

GSK, Bangalore, India.

Ashleigh McGirr (A)

GSK, Mississauga, Ontario, Canada.

Jake N Hunnicutt (JN)

GSK, Collegeville, Pennsylvania, USA.

Christopher L Rowe (CL)

PicnicHealth, San Francisco, California, USA.

Meghan Tierney (M)

PicnicHealth, San Francisco, California, USA.

Haley S Friedler (HS)

PicnicHealth, San Francisco, California, USA.

Classifications MeSH